News-Detail

The American Diabetes Association (ADA) has announced the recipients of this year's National Scientific and Health Care Achievement Awards. Among this year’s awardees is Prof. Timo Müller, Director of the Institute for Diabetes and Obesity (IDO) at…

A new tool developed by Helmholtz Munich and the German Center for Diabetes Research and the University of Bonn makes spatial proteomics and lipidomics easier to use – no coding required. C-COMPASS allows scientists to profile where proteins and…

The medical treatment of obesity and type 2 diabetes is currently undergoing a significant transformation. Innovative drugs such as semaglutide and tirzepatide – often referred to as "weight-loss injections" – mimic the action of specific gut…

Drugs that bind to and activate the receptors for the hormones GLP-1 and GIP are effective in the treatment of obesity and diabetes. Surprisingly, active substances are currently being developed that not only activate the GIP receptor (agonists) but…

The Lancet Diabetes & Endocrinology Commission on Clinical Obesity

A new report of the Commission on Clinical Obesity, published in The Lancet Diabetes & Endocrinology and endorsed by over 75 medical organizations, has introduced a transformative framework that addresses the limitations of traditional BMI-based…

Every year on October 3rd, the German broadcaster WDR organizes the event "Doors Open with The Mouse." This year, 770 companies and research institutions across Germany participated, welcoming children and parents under the theme "Working Together."…

Timo Müller Receives the ADA 2026 Outstanding Scientific Achievement Award

C-COMPASS: AI-Based Software Maps Proteins and Lipids Within Cells

diabinfo in Dialogue: Obesity and Diabetes – Evolving Approaches to Prevention and Treatment

GIP Receptor: Activation and Blockade Support Weight Loss

Re-Defining Obesity as a Disease

Helmholtz Munich Opened Its Doors for "The Mouse"